This white paper argues that life sciences CRM migrations (2026–2029)-driven by Veeva’s move off Salesforce-should not be treated as simple platform cutovers. Instead, they are a once-in-a-decade opportunity to establish a governed system of intelligence that turns CRM engagement data into reusable, trusted enterprise insight.
The core recommendation is additive, not disruptive:
keep Veeva Vault CRM or Salesforce Life Sciences Cloud strong as systems of engagement, while using Databricks as an independent intelligence layer to standardize data, enforce governance, and support analytics and GenAI across commercial, clinical, supply chain, medical, and regulatory functions. This avoids CRM overload, reduces fragmentation, and improves audit readiness.